DRD2 rs1799732: What Your Genotype Means
The rs1799732 variant is a genetic polymorphism located in the promoter region of the DRD2 gene. It is frequently studied for its potential associations with reward-seeking behaviors, personality traits, and susceptibility to various forms of addiction.
What each genotype means
Typical dopamine receptor expression
This genotype represents the insertion/insertion (I/I) state of the DRD2 promoter region. Research suggests this variant may influence dopamine receptor density, which is involved in reward processing and behavioral regulation. Associations with personality traits or medication response are complex and may vary by population; please discuss any concerns regarding medication efficacy with your healthcare provider.
This is the most common genotype, observed in approximately 73% of individuals in some studied populations.
Varied dopamine receptor expression
This genotype represents the insertion/deletion (I/D) state of the DRD2 promoter. Studies have investigated its role in reward-seeking behaviors and potential differences in response to certain medications. Because addiction and behavioral traits are highly polygenic, this genotype alone does not determine outcomes; consult your clinician regarding any specific medication-related questions.
This genotype is found in approximately 25% of individuals in some studied populations.
Reduced dopamine receptor expression
This genotype represents the deletion/deletion (D/D) state of the DRD2 promoter. Some research links this variant to altered dopamine signaling, which may be associated with variations in reward-seeking behavior or treatment response in specific clinical contexts. As these associations are often modest and influenced by many other genetic and environmental factors, please discuss any health or medication concerns with your doctor.
This is the least common genotype, occurring in approximately 1-2% of individuals in some studied populations.
Understanding the rs1799732 Variant
The rs1799732 variant is a single-nucleotide polymorphism (SNP) situated within the promoter region of the DRD2 gene on chromosome 11. In scientific literature, this variant is often described as an insertion/deletion (ins/del) polymorphism, though it is also commonly represented by the alleles C and T. Because it resides in the promoter region—the "on-off switch" area of a gene—researchers hypothesize that this variant may influence how much dopamine D2 receptor protein is produced in the brain. By altering the expression levels of these receptors, the variant may theoretically impact how an individual processes reward signals and dopamine-mediated feedback. While it is a well-documented site of genetic variation, it is important to note that the functional consequences of this specific SNP are complex and likely interact with many other genetic and environmental factors.
The Role of the DRD2 Gene
The DRD2 gene provides the instructions for creating the dopamine D2 receptor, a critical protein in the brain's reward system. Dopamine is a neurotransmitter that acts as a chemical messenger, helping to regulate motivation, pleasure, and motor control. When dopamine binds to D2 receptors, it triggers a cascade of signals that reinforce behaviors, such as eating, socializing, or learning. Because the DRD2 gene is central to these processes, variations in its sequence are frequently investigated in the context of neuropsychiatric conditions and behavioral traits. If the D2 receptor density or sensitivity is altered, it may change how an individual experiences reward, potentially influencing their predisposition toward impulsive or addictive behaviors. Understanding this gene is essential for grasping how our biological hardware contributes to the diverse spectrum of human personality and behavioral health.
Research and Evidence Strength
Evidence linking rs1799732 to specific outcomes is considered moderate and often context-dependent. Research has explored its role in addiction, including studies on opiate dependence and severe alcoholism, where certain genotypes have been associated with increased risk. Other studies have investigated its influence on personality traits, such as harm avoidance in athletes, and even potential links to colorectal adenoma recurrence. However, findings are not always consistent across different populations or study designs. Some research suggests that the variant may modulate how patients respond to certain medications, such as antipsychotics, potentially influencing side effects like weight gain. Because these associations are statistical in nature and often show small effect sizes, they should not be used to predict individual behavior or health outcomes. The field continues to evolve, and current evidence highlights the need for larger, more diverse studies to clarify the clinical significance of this variant.
Population Frequency
The rs1799732 variant is relatively common, with a global minor allele frequency reported at approximately 15% to 23% depending on the population studied. This means that a significant portion of the human population carries at least one copy of the variant allele. Because it is widely distributed, it is considered a common genetic polymorphism rather than a rare mutation. However, frequencies can vary significantly between different ancestral groups, which is a common theme in human genomics. Understanding these frequency differences is important for researchers when designing studies to ensure that findings are representative of diverse populations. If you are interested in your own genetic profile, it is helpful to remember that having a common variant is a normal part of human genetic diversity and does not inherently imply a health condition or a specific behavioral outcome.
Interpreting Your Genetic Information
Genetic information regarding variants like rs1799732 is intended for educational purposes and should not be used for medical diagnosis or personal health management. While research may suggest statistical associations with certain traits or risks, these correlations are rarely deterministic. Many factors, including your environment, lifestyle, and the thousands of other genes in your genome, play a much larger role in shaping your health and behavior. If you have concerns about addiction, mental health, or medication side effects, it is essential to consult with a qualified healthcare professional. If you are curious about how a specific variant might affect your response to a medication, speak with your doctor or pharmacist, as they can provide guidance based on your full clinical history. Never make changes to your prescribed treatments based on genetic data without professional medical supervision.
How common is this variant?
The rs1799732 variant is found globally with a minor allele frequency of approximately 15% to 23%.
Frequently asked questions
Is rs1799732 a test for addiction?
No, rs1799732 is not a diagnostic test for addiction. While some studies show statistical associations between this variant and addiction risk, genetics is only one small piece of a very complex puzzle that includes environment and lifestyle.
Can I change my DRD2 gene expression?
You cannot change your DNA sequence. However, gene expression is dynamic and influenced by many factors, including your environment, stress levels, and overall health, which are managed through clinical care and lifestyle choices.
Should I worry if I have the T allele?
No, having a specific allele is a normal part of human genetic variation. Most people carry many common variants, and they do not necessarily lead to negative health outcomes.
Does this variant affect my medication?
Some research suggests this variant may influence responses to certain medications, such as antipsychotics. If you are concerned about your medication, please discuss your concerns and your genetic information with your prescribing physician or pharmacist.
Sources & further reading
Educational information only, last refreshed 10/2/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1799732?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in DRD2
This SNP in the DRD2 gene is frequently studied in the context of psychiatric genetics, particularly regarding dopamine receptor expression and schizophrenia risk.
This variant has been studied for its association with schizophrenia and dopaminergic signaling.
The TaqIB polymorphism in the DRD2 gene is associated with dopamine receptor density and various behavioral and reward-related traits.
The DRD2 TaqIB variant modulates dopamine D2 receptor density and has been investigated for associations with addiction susceptibility and antipsychotic response.
A synonymous coding variant in exon 7 of DRD2 that affects mRNA stability, translation kinetics, and dopamine-related working memory and reward phenotypes.
Known as the DRD2 TaqID polymorphism, this variant alters D2 dopamine receptor gene structure and is implicated in altered striatal dopamine functioning and substance use behavior.